EXHIBIT 2

Neointimal Tissue Response at Sites of Coronary Stenting in Humans

Macroscopic, Histological, and Immunohistochemical Analyses

Ryushi Komatsu, MD; Makiko Ueda, MD; Takahiko Naruko, MD;
Akiko Kojima, PhD; Anton E. Becker, MD

Background—Experimental animal studies have shown that coronary stenting induces neointimal proliferation. However, the histopathological events after coronary stenting in humans have not been studied systematically.

Methods and Results—We investigated 11 stented coronary arteries (9 Palmaz-Schatz stents, 1 Wiktor stent, and 1 ACS Multi-Link stent) obtained from 11 patients who had died 2 days to 21 months after stenting. We focused on gross, histological, and immunohistochemical aspects of the repair processes. Two patients developed symptoms of restenosis. Serial sections were stained with antibodies against smooth muscle cells (SMCs), macrophages, and endothelial cells. At 9 and 12 days after stenting, the stent sites showed thrombus formation with early formation of neointima composed of abundant macrophages and α-actin–negative spindle cells. From 64 days on, all sites with stenting showed a distinct layer of neointima, albeit to varying degrees. In nonrestenotic lesions, neointimal thickening was markedly less than in restenotic lesions but without qualitative differences; the neointima contained macrophages but was composed predominantly of α-actin-positive SMCs.

Conclusions—These observations strongly support the concept that neointimal proliferation in humans is a process of staged redifferentiation of SMCs, which may cause in-stent stenosis. Moreover, the exuberant neointimal proliferation with accumulation of macrophages and extensive neovascularization at sites of stent restenosis suggests a role for organization of mural thrombus. (***Circulation.*** 1998;98:224-233.)

Key Words: stents ■ restenosis ■ coronary disease ■ immunohistochemistry

Coronary stenting is the only procedure that has been proven to reduce the incidence of late restenosis after PTCA.[1–3] However, thus far only sparse data are available in humans regarding the healing processes involved after stent implantation. Indeed, an enormous gap exists between animal experiments on one hand and insights obtained from observations in humans on the other. In fact, to the best of our knowledge, only 4 autopsy case reports exist of patients who had died 12 hours, 15 days, 3 weeks, and 8 weeks, respectively, after implantation of a coronary stent,[4,5] and in 2 instances, atherectomy specimens, retrieved from restenotic lesions after coronary stenting with a Palmaz-Schatz device, have been reported.[6] Obviously, there is a need for more detailed information in humans.

We are not aware of any systematic studies in humans focusing on gross, histological, and immunohistochemical aspects of the repair processes involved. The present study addresses this need.

Methods

Patients

This study is based on 11 coronary arteries obtained at autopsy from 11 patients who had undergone elective or emergency coronary stenting. The relevant clinical data are summarized in the Table. The mean age of the patients (9 men and 2 women) was 76±6.4 years (range, 66 to 83 years). In 3 patients with acute myocardial infarction (patients 2, 3, and 4), stent implantation was performed to treat coronary dissection after emergency PTCA. One patient (patient 1) with stable angina underwent stenting to treat coronary dissection after PTCA. All 4 patients (patients 1, 2, 3, and 4) showed immediate post-PTCA angiographic evidence of dissection before stent implantation. Two patients (patients 7 and 11) with stable angina underwent primary stenting of a stenotic lesion in the left circumflex coronary artery and in the LAD, respectively. In 1 patient (patient 5) with unstable angina and 90% stenosis of the left main trunk, intracoronary stent implantation was performed because the patient refused to undergo coronary artery bypass grafting. In the 4 remaining patients (patients 6, 8, 9, and 10), stent implantation was performed for restenosis after PTCA. In these 11 patients, the interval between coronary stenting and death ranged from 2 days to 21 months.

A Palmaz-Schatz stent (Johnson & Johnson Interventional System) was inserted into 9 sites. One coronary artery received a Wiktor stent (Medtronic Inc); the remaining artery contained an ACS Multi-Link stent (Advanced Cardiovascular Systems).

All patients with coronary stents were treated initially with heparin and then maintained on different drug regimens: heparin only (patients 1, 2, 3, and 5); aspirin only (patient 11); aspirin and ticlopidine (patients 4 and 8); aspirin, warfarin, and dipyridamole (patient 9); and warfarin only (patients 6, 7, and 10). High-pressure

Received January 6, 1998; revision received March 2, 1998; accepted March 17, 1998.

From the Department of Pathology, Osaka City University Medical School (R.K., M.U.); the Department of Cardiology, Osaka City General Hospital (T.N.); the Department of Food and Nutrition, Faculty of Human Life Science, Osaka City University (A.K.), Osaka, Japan; and the Department of Cardiovascular Pathology, Academic Medical Center, University of Amsterdam, the Netherlands (A.E.B.).

Correspondence to Dr Makiko Ueda, Department of Pathology, Osaka City University Medical School, 1-4-54 Asahi-machi, Abeno-ku, Osaka, 545, Japan.

Selected Abbreviations and Acronyms
LAD = left anterior descending coronary artery
PDGF = platelet-derived growth factor
SMC = smooth muscle cell
vWF = von Willebrand factor

stent dilatation, which recently became standard, was performed in 6 patients (patients 3, 6, 7, 8, 10, and 11).

Two patients (patients 7 and 8) developed recurrent angina pectoris, which was electrocardiographically related to the stented coronary artery. The signs and symptoms were considered indications of restenosis; angiography, however, could not be done in any of these patients.

Histological Investigations

In 9 of the 11 patients, the whole heart was available for study. The site of stenting was identified by comparing the clinical angiograms with the heart specimens. The coronary arteries were removed from the epicardial surface, and the site containing the stent was cut with scissors into 5-mm segments. Care was taken to have the articulation of the Palmaz-Schatz stent within 1 of these segments. In the present study, designed to investigate the cellular components at the stenting site with specific immunohistochemical techniques, we did not select an embedding method in methyl methacrylate recommended for obtaining intact cross sections.[7] In 4 hearts, the coronary artery segments were fixed in buffered formalin; in the remaining 5 hearts, the segments were fixed in methanol-Carnoy's fixative.

After fixation, the stent fragments on the cut surface of each of the 5-mm segments were removed under a dissection microscope. Each 5-mm segment was then routinely processed and embedded in paraffin. From each segment, sections were cut at 8- or 10-μm thickness. Each time a portion was encountered that still contained residual stent fragments, these fragments were removed carefully, again by cutting the fragments and pulling them out of the paraffin-embedding block; thereafter, the sectioning continued. From each segment, ≈100 to 300 sections were cut. This procedure thus allowed us to obtain an adequate overview of all the stented arterial segments.

In the remaining 2 patients (patients 5 and 9), only paraffin blocks from the sites of coronary stenting were available for the study; microscopic sections were made by use of the same method as described above. Of these sections, every 20th and 21st sections were stained with hematoxylin-eosin and Weigert's elastic van Gieson's stain, respectively. The other sections were used for immunohistochemical staining.

Immunohistochemical Investigations

Single Staining

The cellular components were analyzed by use of monoclonal antibodies against actin (1A4, HHF-35, and CGA-7), vimentin, macrophages (HAM-56 and PGM-1), and endothelial cell vWF. The 3 actin markers were used to study the state of differentiated SMCs. 1A4 and HHF-35 are markers that are the first to become positive when SMCs differentiate toward the contractile phenotype; once fully differentiated as such, CGA-7 also becomes positive.[8–10] Sections were incubated with the primary antibody for 1 hour at room temperature. The sections were then subjected to a three-step staining procedure with the use of streptavidin-biotin complex with horseradish peroxidase for color detection. Buffered saline was used for washing between the subsequent incubation steps. Horseradish peroxidase activity was visualized with 3-amino-9-ethylcarbazole, and the sections were counterstained faintly with hematoxylin.

Double Staining

For the simultaneous identification of SMCs and macrophages, the following subsequent incubation steps were performed: normal goat serum (15 minutes), blotting, no washing, cocktail of 2 primary monoclonal antibodies (anti-SMC α-actin, 1A4 [IgG2a] and anti-macrophage, HAM-56 [IgM] for 60 minutes), cocktail of 2 secondary antibodies consisting of biotinylated goat anti-mouse IgG2a and alkaline phosphatase–conjugated goat anti-mouse IgM (30 minutes), and β-galactosidase–labeled streptavidin (30 minutes). The enzymatic activity of β-galactosidase for 1A4 (IgG2a) was visualized in turquoise (BioGenex Kit, San Ramon), and that of alkaline phospha-

Clinical Data Relevant to This Study of 11 Patients Who Underwent Coronary Artery Stenting

Patient	Age, y	Sex	Indication for Stent	Stent Site	PTCA, n	Interval PTCA/Stent	Interval Stent/Death	Cause of Death	Poststent Restenosis	Stent Type
1	72	M	SAP, failed PTCA	LMT	1	Within 30 min	2 d	Acute thrombosis and shower embolism		Wiktor
2	82	M	AMI, failed PTCA	LAD	1	1 d	6 d	Subacute thrombosis		Palmaz-Schatz
3	69	M	AMI, failed PTCA	LAD	1	Within 30 min	9 d	Subacute thrombosis		Palmaz-Schatz
4	75	M	AMI, failed PTCA	RCA	1	Within 30 min	12 d	Subacute thrombosis		Palmaz-Schatz
5	66	M	UAP	LMT	0	0	30 d	Pneumonia	–	Palmaz-Schatz
6	83	M	Restenosis after PTCA	LAD	1	57 d	64 d	Sudden death	–	Palmaz-Schatz
7	83	M	SAP	LCx	0	0	85 d	Pneumonia	+	ACS Multi-Link
8	68	M	Restenosis after PTCA	RCA	2	6 mo/9 mo	5 mo	Sudden death	+	Palmaz-Schatz
9	73	F	Restenosis after PTCA	LAD	1	5 mo	12 mo	Cerebral hemorrhage	–	Palmaz-Schatz
10	80	M	Restenosis after PTCA	LAD	1	56 d	15 mo	Lung cancer	–	Palmaz-Schatz
11	81	F	SAP	LAD	0	0	21 mo	Sudden death	–	Palmaz-Schatz

SAP indicates stable angina pectoris; LMT, left main truncus; AMI, acute myocardial infarction; RCA, right coronary artery; UAP, unstable angina pectoris; and LCx, left circumflex artery.



Figure 1. Segment of the LAD 9 days after PTCA and stenting with complete thrombotic occlusion [illegible]. Gross aspect of a cross section that reveals total occlusion of the lumen by thrombus. There is an eccentric atherosclerotic plaque. B, Histological section from the cut surface shown in A. The lumen contains an occlusive thrombus (T), which relates to the site of stenting (stent struts indicated by arrowheads). At the site of the stent struts, there is no cellular reaction, whereas the site of the PTCA-related medial dissection (arrow) shows distinct neointimal proliferation (asterisk). AS indicates preexisting atherosclerotic plaque. Elastic tissue stain. Magnification B, ×55.

tase for HAM-56 (IgM) was visualized in red (New Fuchsin Kit, Dako).[11]

Results

Palmaz-Schatz Stent (Nine Sites)

Three patients who had undergone emergency Palmaz-Schatz stenting after failed PTCA clinically developed subacute thrombosis 6 to 12 days after stenting. Gross investigation confirmed occlusive thrombus formation at the site of the stent (Figure 1). Light microscopical study showed that all sites contained a preexisting eccentric plaque and revealed that the struts of the stent had lacerated the arterial wall and caused a local response. At 6 days after stenting (patient 2), the site of the struts showed thrombus formation and an accumulation of macrophages around the struts. At 9 and 12 days after stenting (patients 3 and 4), the stent sites at the site of the thrombus revealed only minimal cellular reaction around the struts, whereas the stent sites proximal or distal to the thrombus showed a more prominent cellular reaction mixed with mural thrombus (Figure 2). In the latter, the cellular reaction was characterized by an early proliferation of neointimal tissue composed of abundant macrophages and actin-negative spindle-shaped cells, which stained posidve for vimentin but negative with actin markers 1A4, HHF-35, and CGA-7 (Figure 2B through 2D). No positivity with the antibody against vWF was found at the luminal surface of the neointimal tissue (Figure 2E). Moreover, in these 3 patients, PTCA-related medial dissection at the border area between the plaque wall and plaque-free wall of a stented eccentric plaque was observed. The neointima alongside the dissection was also composed of macrophages and spindle-shaped cells, most of which were negative for the actin markers.

At 30 days after stenting (patient 5), the areas around the struts still contained remnants of thrombus, but there was distinct proliferation of α-actin–positive SMCs, with only occasional macrophages. No vWF-positive cells, covering the neointima, were observed at this site.

From 64 days on (patients 6, 8, 9, 10, and 11), all sites with stenting showed a distinct layer of neointimal tissue, albeit to varying degrees. In 4 lesions without clinical evidence of restenosis (patients 6, 9, 10, and 11; 64 days and 12, 15, and 21 months after stenting, respectively), the thickening of the neointimal tissue was distinctly less than in restenotic lesions (Figures 3 through 5; compare with Figure 6). In these nonrestenotic lesions, the neointima was composed predominantly of α-actin–positive SMCs, with some macrophages and foreign body giant cells located adjacent to the struts. The lesion at 64 days, moreover, showed fibrin, considered a remnant of a previous thrombus, within the neointima close to the luminal surface (Figure 3); no remnants of thrombus were found within the neointima at 12, 15, and 21 months after stenting (Figures 4 and 5). In the lesion at 64 days, positive staining with the anti-vWF antibody was observed partially at the luminal surface of the neointima. However, in lesions at 12, 15, and 21 months, a complete lining of vWF-positive endothelial cells was found at the luminal surface (Figure 5).

The site with clinical restenosis after stenting (patient 8; 5 months after stenting) presented exuberant neointimal formation, resulting in almost total occlusion (Figure 6). The neointima contained newly formed microvessels and scattered macrophages, particularly in the deep layers with extensive accumulation of SMCs. This patient had PTCA-related restenosis and thus had undergone stenting. The neointima formed after PTCA before stenting was clearly identified adjacent to the stent struts and distinct from the neointima induced by stenting. In fact, because of stent implantation, the post-PTCA neointima was markedly compressed, partially disrupted, and covered by a second neointima, which accounted for the post stent neointima (Figure 6).

Wiktor Stent (Patient 1, 1 Site)

The site 2 days after stenting showed occlusive intravascular thrombosis. Microscopically, PTCA-related medial dissec-



Figure 2. Segment of the LAD of the same patient shown in Figure 1, 9 days after PTCA and stenting, which is taken more proximally and shows partial thrombotic adherence. A through E are serial sections. A, Hematoxylin–eosin stain. There is a distinct neointima (asterisks) with adherent mural thrombus at the site of a stent strut (arrowhead). B, Staining for vimentin reveals that the cells of the neointima are positive for vimentin. C, Anti-HHF-35. The spindle-shaped cells within the neointima do not stain with the α-actin marker at this stage (compare with B). D, Anti-HAM-56. The neointima contains HAM-56–positive macrophages. E, Anti-vWF. There are no positive-staining endothelial cells at the luminal surface of the neointima. There is positive staining of endothelial cells of the vasa vasorum (arrow), shown at higher magnification in the inset. Magnification A through D, ×110; E, ×72; inset E, ×217.

tion was present, and the stent struts had caused additional local laceration of the arterial wall.

ACS Multi-Link Stent (Patient 7, 1 Site)

The patient developed clinical signs and symptoms of restenosis and died 85 days after stenting. Gross and microscopic evaluations showed excessive neointimal formation, causing almost total occlusion (Figure 7). At the site of restenosis, the deep layers of the neointima contained abundant microplunges and newly formed capillaries, whereas the superficial layers consisted almost entirely of SMCs (Figure 7).

Discussion

To the best of our knowledge, the present study, based on 11 stented sites in 11 patients and with an interval between stent implantation and death ranging from 2 days to 21 months, is the first systematic investigation into the pathobiology of stent stenosis in humans. Several aspects need further consideration. To this end, we will consider all 11 stents together, because the vast majority (9 of 11) were Palmaz-Schatz stents.

Subacute Thrombosis

Our series contains 4 patients (patients 1, 2, 3, and 4) in whom (sub)acute thrombosis after stenting had occurred. It is interesting that each of these 4 patients received stents because of a failure of a PTCA procedure that in each patient had led to a dissection extending into the media. Indeed, in patients in whom stenting is performed as a bailout procedure after PTCA failure, the reported incidence of thrombosis is relatively high and varies between



Figure 3. Segment of the LAD 64 days after stenting (patient 6 in the table). A, Gross aspect of a cross section showing an eccentric atherosclerotic plaque (AS) and neointima surrounding stent struts. B, Elastic tissue stain of the same cut surface shown in A. There is a distinct, eccentric atherosclerotic plaque. The site of a stent strut (arrowhead) is covered by neointima (asterisks). C, Higher magnification of the area containing the arrowhead shown in B. The site of the strut is distinct (arrowhead), and the area around the strut contains neointima with fibrin as remnants of previous thrombosis (T) close to the luminal surface. Hematoxylin-eosin stain. D, Immunodouble staining with 1A4 (turquoise) and HAM-56 (red) from the same site shown in C. The neointima around the strut (arrowhead) is composed mainly of SMCs with occasional macrophages. Magnification B, ×21; C and D, ×82.

6.9%[15] and 16%.[13] The question remains what mechanisms underlie the relationship between the initial PTCA-related medial dissection and the occurrence of subacute thrombosis after stenting.

Late Stent Stenosis

This study of human coronary arteries suggests that the sequence of events leading to a neointima formation after implantation of stents is basically similar to that encountered



Figure 4. Segment of the LAD 15 months after stenting (patient 10 in the Table). A, Gross aspect of a cross section shows an eccentric atherosclerotic plaque (AS) and distinct neointimal proliferation around the struts of the stent. B, Immunodouble stain of the same cross section shown in A, with 1A4 (turquoise) and HAM-56 (red). The neointima (asterisks) consists mainly of SMCs. The sites of the stent struts are indicated by arrowheads. Magnification B, ×18.



Figure 5. Segment of the LAD 21 months after stenting (patient 11 in the Table). A, Gross aspect of a cross section shows an eccentric atherosclerotic plaque (AS) and extensive neointimal formation with considerable luminal narrowing. The stent struts are clearly visible within the neointima. B, Elastic tissue stain of the section shown in A. There is extensive neointimal tissue (asterisks) around the stent struts (arrowheads). C, Same section as shown in B immunostained with 1A4. The neointima around the stent struts (arrowheads) is composed almost totally of SMCs. D, Staining for vWF. The luminal surface of the neointima is lined by vWF-positive cells, considered regenerated endothelial cells. Magnification B and C, ×33; D, ×368.

in animal models[14–16] and is very similar to that observed in post-PTCA repair processes.[6–10,17] In general terms, the initial event is that of local thrombus formation, adjacent to the stent struts, gradually invaded by cellular components such as macrophages and α-actin–negative spindle-shaped cells accompanied by the deposition of extracellular matrix components. This eventually differentiates into a much more fibrocellular lesion containing α-actin–positive SMCs. These observations strongly suggest that mural thrombosis with macrophage infiltration at the earliest stage after stenting may be crucial in recruiting SMCs from the arterial wall. Indeed, platelet adherence and aggregation promote the subsequent healing process through the release of growth factors.[18–20] Macrophages also secrete a variety of cytokines and growth factors that have been shown in vitro to cause SMC proliferation and migration.[21,22] Experimental animal studies have suggested that PDGF, secreted not only from activated platelets but also from macrophages and other vascular cells, is 1 of the major growth factors involved in the process of neointimal formation after balloon injury.[23–25] Furthermore, our own in situ hybridization and immunohistochemical studies of human coronary arteries after PTCA using frozen sections have shown that PDGF-A and -B mRNAs, PDGF-B protein, and PDGF-β receptor protein are expressed in neointimal lesions containing macrophages and actin-negative spindle-shaped cells.[10,26] Whether similar phenomena occur in the process of neointimal formation in human coronary arteries after stenting is unknown, but the possibility is intriguing, and future studies using frozen sections obtained from stenting sites should look into these aspects.

In 1987 in their study of coronary arteries of dogs, Schatz and coworkers[16] considered intimal hyperplasia a consequence of intense fibroblast proliferation at 8 weeks after stenting. The present study in humans, using immunocytochemical markers, clearly shows that cellular components invading the thrombotic aggregates at the sites of laceration at the earliest stages are spindle-shaped cells negative for actin markers such as HHF-35 and 1A4. However, at 30 days, a neointima is clearly identifiable, and the spindle-shaped cells present within this layer appear to be positive with both actin markers. This sequence strongly suggests that during the evolution of the neointima, the α-actin–negative spindle-shaped cells most likely represent dedifferentiated SMCs, which in time gradually redifferentiate into α-actin–positive SMCs. This concept of staged redifferentiation of neointimal SMCs is endorsed by experimental studies[27,28] and is relevant because we previously demonstrated almost identical shifts in the cytoskeletal phenotype of spindle-shaped cells during the



Figure 6. Segment of the right coronary artery 6 months after stenting, with restenosis (patient 8 in the Table). A, Gross aspect of a cross section shows almost total occlusion caused by excessive neointimal proliferation. B, Histology of the cross section shown in A. There is exuberant neointimal formation related to the stent procedure ("stent"). The sites of stent struts are indicated by arrowheads. The previous PTCA procedure had caused distinct laceration of the preexistent wall, which has resulted in post-PTCA neointima ("PTCA") with a much more compact structure with a much higher density of collagen. The post-PTCA neointima is markedly compressed by the implanted stent. Elastic tissue stain. C, Hematoxylin-eosin stain. The neointima formed around the stent struts (arrowheads) contains distinct microvessels. D, Immunodouble stain with 1A4 (turquoise) and HAM-56 (red) shows an extensive accumulation of SMCs around the stent struts (arrowheads) with scattered macrophages and numerous microvessels in the deeper layers of the neointima. E, Staining for vWF. Around the stent struts (arrowheads), abundant microvessels are seen that stain positive with anti-vWF. AS indicates preexisting atherosclerotic plaque. Magnification B, X18; C, X62; D and E, X132.

development of the neointima after angioplasty injury in human coronary arteries.[17] It could be argued that the α-actin–negative spindle-shaped cells observed early in the neointima might represent not only dedifferentiated SMCs but also other cell types such as infiltrating macrophages that have lost their specific antigen or fibroblasts—a point of view that at this stage, cannot be elucidated.

Despite similarities between experimental animal models and humans, the present study also shows important differences in the healing phenomena after stenting. First, a restenotic lesion, which occurred 85 days after implantation of the ACS Multi-Link stent (patient 7) and 5 months after implantation of a Palmaz-Schatz stent (patient 8), showed excessive neointimal proliferation composed of numerous macrophages; SMCs; and abundant, newly formed microvessels, which led to almost total occlusion of the lumen (Figures 6 and 7). It is the quantity of these features that makes them exceptional; neovascularization and macrophages with occasional giant cells are common findings, particularly adjacent to stent wires, in both experimental animal models[14] and this study in human coronary arteries. These observations are of interest because both sites of restenosis after stent implantation show large numbers of macrophages and extensive neovascularization, features not observed to this extent at "nonrestenotic" stent sites. In this context, it is important that Moreno and associates[20] recently showed that the amount of macrophages in preexistent atherosclerotic lesions is a predictor for restenosis after PTCA. Previously, Strauss et al[9]



Figure 7. Segment of the left circumflex artery 85 days after stenting with restenosis (patient 7 in the Table). A, Gross aspect of a cross section shows almost total occlusion at the site of stenting caused by exuberant neointimal proliferation. B, Elastic tissue stain of the cut surface shown in A. The excessive neointimal proliferation (asterisks) is distinct and is seen to cause restenosis. The site of the stent struts is indicated by arrowheads. C, Immunodouble staining with 1A4 (turquoise) and HAM-56 (red) shows that the superficial layer of the neointimal proliferation is composed almost entirely of SMCs, whereas the deep layers, close to the stent struts (arrowheads), contain numerous macrophages (see E). D, Staining for vWF shows that the neointima contains an almost concentric layer of neovascularization in the deep parts. The stent struts are indicated by arrowheads. The luminal surface also contains vWF-positive cells, considered regenerated endothelial cells. E, Immunodouble staining with 1A4 (turquoise) and HAM-56 (red) shows, at higher magnification, the area indicated between arrows in C. The site of the stent strut is indicated by an arrowhead. Note the accumulation of macrophages (red) and the more superficial dominance of SMCs (turquoise). F, Staining for vWF. The area indicated between arrows in D is shown at higher magnification. An arrowhead indicates the site of the stent strut. Note the vWF-positive microvessels present in the deep layers. AS indicates preexisting atherosclerotic plaque. Magnification B, ×16; C and D, ×62; E and F, ×147.

compared coronary atherectomy material obtained from patients with restenosis after stenting with that obtained from patients with restenosis after angioplasty or atherectomy. They concluded that SMC proliferation was the predominant feature in restenotic tissue regardless of the initiating procedure and without any unique features attributable to stenting in general or to a particular type of stent. This apparent controversy is of considerable interest. We have indicated previously that once the post-PTCA laceration, particularly in concentric lesions, is limited to the atheroma, the repair

process is often accompanied by neovascularization and accumulation of macrophages in the deeper parts of the neointima.[10,17,20] Hence, the formation of a concentric layer of neovascularization and macrophage accumulation in the deep parts of the neointima may result from organization processes of thrombosis, which initially was formed around the stent wires at the sites of initial laceration. Accumulation of SMCs at the luminal side follows at a later stage.

Another difference with the earlier experiments by Schatz and coworkers[18] performed on normal coronary arteries in dogs is that in their series, the maximal neointimal thickness occurred at 8 weeks after stent implantation; this was followed by sclerotic changes with less cellularity and marked regression of the neointima by 32 weeks.[16] However, in our series of human coronary arteries, each containing atherosclerotic disease, we observed lesions with intervals between stent implantation and death ranging from 12 to 21 months, and each showed distinct cellularity composed predominantly of α-actin–positive SMCs without obvious sclerotic changes. These observations clearly indicate that fibrosclerosis as seen in normal dog arteries certainly cannot be considered the rule in human atherosclerotic coronary arteries, at least not within the limits of our study, which is 2 years after stenting. It remains to be settled in future studies with more cases whether the differences between our observations and those obtained in dogs relate merely to species differences or to the fact that normal arteries in dogs cannot be considered to represent the basic mechanisms that underlie poststenting neointimal formation in atherosclerotic lesions in humans.

In the experimental dog model used by Schatz and coworkers,[16] reendothelialization after stenting, using the scanning electron microscope, appeared incomplete at 1 week. At 3 weeks, a mosaic type of endothelial cell lining was found, and full endothelial covering with mature and elongated cells was seen at 32 weeks.[16] Thus far, 1 autopsied case, 8 weeks after a Palmaz-Schatz stent implantation, also reports a neointima covered by endothelial cells overlying the area of the stent.[1] However, there is no immunohistochemical identification of these endothelial cells. In the present study, with regard to immunostaining characteristics with anti-vWF antibody, nonrestenotic lesions after stenting revealed partial endothelial cell regeneration at 64 days and complete restoration of the endothelial cell lining in lesions at 12, 15, and 21 months after stenting. Further studies with more cases are needed to clarify a more detailed time course of reendothelialization at the site of coronary stenting in humans. Nevertheless, the present study, for the first time, provides immunohistochemical data regarding reendothelialization after stenting in human coronary arteries.

Restenosis Versus Nonrestenosis

Previous studies have suggested that chronic stent recoil may contribute significantly to stent restenosis.[31,32] However, recent serial intravascular ultrasound studies have demonstrated that chronic stent recoil is minimal and that late luminal loss and in-stent restenosis are the result of neointimal tissue proliferation.[33–35] In the present study, neointimal proliferation was present from 9 days after stenting on. The salient histological features were basically the same whether restenosis had developed or not. Indeed, from this small series, it appears that the differences between restenosis and "nonrestenosis" are quantitative rather than qualitative. Be that as it may, the observations presented here strongly support the concept that stent stenosis is caused by neointimal proliferation.

Study Limitations

This study represents only a limited number of autopsied cases obtained from patients after implantation of a coronary artery stent, most of which were Palmaz-Schatz stents. We presented only 1 case with a Wiktor stent and 1 with an ACS Multi-Link stent. The question arises, therefore, whether the findings obtained at the site of stenting with the Palmaz-Schatz stent apply to other stents; the observations suggest that this is so, but the limited number of cases does not allow a firm statement to this end.

References

1. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS, Walker C, Stagg J, Buchbinder M, Teirstein PS, Topol EJ, Savage M, Perez JA, Curry RC, Whitworth H, Sousa JE, Tio F, Almagor Y, Ponder R, Penn IM, Leonard B, Levine SL, Fish RD, Palmaz JC. Clinical experience with the Palmaz-Schatz coronary stent: Initial results of a multicenter study. *Circulation*. 1991;83:148–161.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. *N Engl J Med*. 1994;331:489–495.
3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovitch A, Hirshfeld J, Bailey S, Ake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med*. 1994;331:496–501.
4. Anderson PG, Bajaj RK, Baxley WA, Roubin GS. Vascular pathology of balloon-expandable flexible coil stents in humans. *J Am Coll Cardiol*. 1992;19:372–381.
5. Hasdai D, Garratt KN, Holmes DR Jr, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombosis are of limited efficacy in resolving early intracoronary stent thrombosis. *J Am Coll Cardiol*. 1996;28:361–367.
6. Strauss BH, Umans VA, van Suylen RJ, de Feyter PJ, Marco J, Robertson GC, Renkin J, Heyndrickx G, Vuzevski VD, Bosman FT, Serruys PW. Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. *J Am Coll Cardiol*. 1992;20:1465–1473.
7. van Beusekom HMM, Whelan DM, van de Plus M, van der Giessen WJ. A practical and rapid method of histological processing for examination of coronary arteries containing metallic stents. *Cardiovasc Pathol*. 1996; 5:69–76.
8. Ueda M, Becker AE, Tsukada T, Numano F, Fujimoto T. Fibrocellular tissue response after percutaneous transluminal coronary angioplasty: an immunocytochemical analysis of the cellular composition. *Circulation*. 1991;83:1327–1332.
9. Ueda M, Becker AE, Nuruko T, Kojima A. Smooth muscle cell de-differentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans. *Comm Artery Dis*. 1995;6:71–81.
10. Tanizawa S, Ueda M, van der Loos CM, van der Wal AC, Becker AE. Expression of platelet derived growth factor B chain and β receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. *Heart*. 1996;75:549–556.
11. van der Loos CM, Becker AE, van den Oord JJ. Practical suggestions for successful immunoenzyme double-staining experiments. *Histochem J*. 1993;25:1–13.

12. Schomig A, Kastrati A, Mudra H, Blasini R, Schuhlen H, Klauss V, Richardt G, Neumann FJ. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. *Circulation*. 1994;90:2716–2724.
13. Hofmann HC, Buchbinder M, Cleman MW, Fischman D, Goldberg S, Leon MB, Schatz RA, Tierstein P, Walker CM, Kleshfeld JW Jr. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. *Circulation*. 1992;86:812–819.
14. Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft: a preliminary study: work in progress. *Radiology*. 1985;156:73–77.
15. Palmaz JC, Windeler SA, Garcia F, Tio FO, Sibbitt RR, Reuter SR. Atherosclerotic rabbit aortas: expandable intraluminal grafting. *Radiology*. 1986;160:723–726.
16. Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. *Circulation*. 1987;76:450–457.
17. Ueda M, Becker AE, Fujimoto T, Tsukada T. The early phenomena of restenosis following percutaneous transluminal coronary angioplasty. *Eur Heart J*. 1991;12:937–945.
18. Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during degranulation and action on vascular smooth muscle cells. *J Cell Biol*. 1986;102:1712–1738.
19. Daniel TF. Polypeptide growth factors: roles in normal and abnormal cell growth. *Annu Rev Cell Biol*. 1987;3:443–492.
20. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF in blood clots during dissolution with plasmin. *Nat Med*. 1995;1:932–937.
21. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis, a special case of atherosclerosis progression. *Circulation*. 1992;86(suppl I(I)):III-47–III-53.
22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature*. 1993;362:801–809.
23. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. *Science*. 1991;253:1129–1132.
24. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. *J Clin Invest*. 1992;89:507–511.
25. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. *Arterioscler Thromb*. 1993;13:1218–1226.
26. Ueda M, Becker AE, Kasayuki N, Kojima A, Morita Y, Tanaka S. In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. *Am J Pathol*. 1996;149:831–843.
27. Kocher O, Gabbiani F, Gabbiani G, Reidy MA, Cokay MS, Peters H, Huttner I. Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening: biochemical and morphologic studies. *Lab Invest*. 1991;65:459–470.
28. Watanabe H, Dingemans KP, Becker AE, Ueda M, Naruko T, Tanizawa S, Nakamura K. Is the Watanabe heritable hyperlipidemic rabbit a suitable experimental model for percutaneous transluminal coronary angioplasty in humans? A light microscopic, immunohistochemical and ultrastructural study. *J Am Coll Cardiol*. 1993;21:1490–1496.
29. Bai H, Masuda J, Sawa Y, Nakano S, Shirakura R, Shimazaki Y, Ogata J, Matsuda H. Neointima formation after vascular stent implantation: spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation. *Arterioscler Thromb*. 1994;14:1846–1853.
30. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IR, Fuster V, Fallon JT. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. *Circulation*. 1996;94:3098–3102.
31. Bonner RF, Keren G, Douek PC, Leon MB. Acute and chronic compression of rigid slotted stents accounts for progressive lumen narrowing. *Circulation*. 1991;84(suppl II):II-197. Abstract.
32. Keren G, Pichard AD, Kent KM, Satler LF, Leon MB. Failure or success of complex catheter-based interventional procedures assessed by intravascular ultrasound. *Am Heart J*. 1992;123:200–208.
33. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and reablation within coronary stents quantitative angiographic assessment. *J Am Coll Cardiol*. 1993;21:1166–1174.
34. Painter JA, Mintz GS, Wong SC, Popma JJ, Pichard AD, Kent KM, Satler LF, Leon MB. Serial intravascular ultrasound studies fail to show evidence of chronic Palmaz-Schatz stent recoil. *Am J Cardiol*. 1995;75:398–400.
35. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. *Circulation*. 1996;94:1247–1254.